Related: W.L. Gore to acquire left atrial appendage device maker Conformal Medical

This milestone expands on the April 1, 2025 formation of VB Spine, established through the acquisition of Stryker’s U.S. spine implant business. VB Spine operates independently under the leadership of Marc, John, and Anthony Viscogliosi, co-founders of Viscogliosi Brothers, LLC.

The acquisition brings with it the site’s people, infrastructure, and processes. It also creates opportunities to expand VB Spine’s medical education and training programs in Europe.

“The team in Cestas brings deep expertise and a strong track record in manufacturing excellence,” said John Viscogliosi, co-CEO of VB Spine. “We’re thrilled to welcome them to VB Spine and excited for the role they will play in our future. Cestas will anchor our worldwide manufacturing capabilities and give us a strong platform to deliver training and best practices to surgeons.”

Transition Highlights:

• Employees transitioned from Stryker to VB Spine
• Manufacturing operations continue without interruption
• Integration planning is well underway to align systems, quality, and supply chain

With the Cestas facility now part of VB Spine, the company expands its global presence and strengthens its commitment to advance spine care globally.

Forward-Looking Statements

Certain statements in this release are forward-looking and are based on current expectations, forecasts, and assumptions. Actual results may differ materially due to regulatory, commercial, and operational risks. VB Spine disclaims any obligation to update forward-looking statements except as required by law.

Transaction Financing

Viscogliosi Brothers, LLC and Viscogliosi Brothers Watermark Holdings LLC are equity investors in VB Spine.

The post VB Spine completes acquisition of Cestas manufacturing facility from Stryker appeared first on Medical Device News by Guided Solutions.

The move unites DatCard and Sorna’s expertise in clinical data sharing with Avandra’s platform for aggregating de-identified patient data to support medical research, AI development, and clinical advancement.

Related: FluidAI Medical announces an acquisition deal with Emmetros Limited

DatCard and Sorna will continue to function as independent entities under the Avandra brand.

Together, they offer services to most of the academic medical centres in the US, including more than half of the National Cancer Institute sites.

DatCard provides Digital Imaging and Communications in Medicine (DICOM) distribution technology, which assists healthcare organisations in sharing imaging data to maintain continuity of care and support patient outcomes.

The company’s PacsCube product is currently installed at over 4,800 locations worldwide.

Sorna is focused on automated medical data distribution. Its Vertex Platform includes a range of applications such as cloud-brokered data sharing, intelligent patient information routing, and automated DICOM CD production.

Sorna Corporation founder and Avandra senior adviser Cyrus Samari said: “We were looking for an organisation with a clear strategic plan and a genuine appreciation for Sorna’s team, products, customers, and partners.”

Avandra Health CEO Ryan Tarzy said: “By bringing together DatCard, Sorna, and Avandra, we’re creating the industry’s first comprehensive medical imaging platform that serves both immediate patient care needs and long-term research innovation.

“This combination enables us to unlock the full potential of medical imaging to transform healthcare delivery and accelerate life-saving research, while continuously improving the tools and support that clinicians depend on daily.”

Avandra has indicated plans for significant investment in innovation across its platforms, with a focus on the development of new products, feature improvements, and customer support.

The company was established last year by Aegis Ventures and CEO and founder Ryan Tarzy.

The post Avandra creates medical imaging platform with new acquisitions appeared first on Medical Device News by Guided Solutions.

Chicago-based GE HealthCare plans to complete the deal in cash as it looks to add cloud-enabled and AI-powered imaging solutions. It says the deal furthers its aim to triple its offerings of cloud-enabled products by 2028.

Intelerad provides imaging software and digital enterprise workflow solutions. it has a significant presence in outpatient ambulatory care settings. The company offers cloud-first products designed for radiology and cardiology that span the inpatient and outpatient care settings.

Related: Okami secures $45m to advance clinical programmes for vascular disease

GE HealthCare said Inelerad’s outpatient footprint complements its own leadership in hospital-based imaging. Combined, the company expects these capabilities to create a more comprehensive, cloud-first and AI-enabled imaging offering. It expects this to span diverse care settings, from leading academic medical centers to expanding ambulatory networks.

According to a news release, the deal enables GE HealthCare to expand into a $2 billion-plus growth segment.

GE HealthCare expects Intelerad to deliver $270 million in revenues in its first full year of ownership. Approximately 90% of that registers as recurring, while it expects revenue growth in the low-double-digit range annually, with acceleration under GE HealthCare’s ownership.

Upon close, the company expects an immediately accretive impact to top-line growth and adjusted earnings before interest and taxes (EBIT) margin. It anticipates a slightly dilutive impact to adjusted earnings per share in the short term, inclusive of the impact of financing costs. The company plans to offset this with cost efficiencies. It anticipates a high-single-digit return on invested capital by year five.

The company expects to complete the acquisition in the first half of 2026.

Roland Rott, president and CEO of Imaging at GE HealthCare, said: “Intelerad is an outstanding strategic fit and is a pioneer in cloud-based imaging software, with a strong portfolio of world-class solutions across care settings. By combining GE HealthCare’s medical device and AI competence at global scale with Intelerad’s enterprise cloud and imaging expertise, we will be even better positioned to meet the evolving needs of healthcare providers, simplify complex workflows, and drive digital innovation across the industry.”

Jordan Bazinsky, CEO of Intelerad, said: “Joining GE HealthCare marks an exciting new chapter for Intelerad. GE HealthCare’s global scale and extensive relationships with key decision makers across hospital systems will fuel the expansion of our connected imaging software offering. Together, we look forward to advancing digital innovation in healthcare and delivering more integrated AI-enabled solutions that empower our customers to tackle their greatest challenges.”

The post GE HealthCare to advance enterprise imaging through Intelerad acquisition appeared first on Medical Device News by Guided Solutions.

Reports circled as recently as last month that Siemens was considering this move, although the company has been having discussions around the future of the Healthineers business since at least late last year.

The European tech giant currently has an approximately 67% stake in the medical technology unit. It plans to transfer 30% of Siemens Healthineers shares to Siemens AG shareholders by way of a direct spin-off as a preferable option. As a result, Siemens shareholders benefit directly and receive shares in Siemens Healthineers.

Related: Organon divests JADA system to Laborie in $465m deal

Siemens Healthineers currently stands as the world’s fourth-largest medtech company, bringing in more than $24 billion in annual revenue.

CEO Bernd Montag said in a LinkedIn post that the move marks the “natural next step” in the company’s journey to becoming a fully independent company, which it started with its IPO in 2018.

“As a publicly listed leader in medical technology, we as Siemens Healthineers have steeply grown our relevance for customers and patients, made transformative moves like our combination with Varian, and created a unique culture and outstanding employee engagement around our purpose: We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably,” Montag wrote.

“We are excited to enter our new strategy phase – elevating – with an even clearer profile for our customers and their patients, and for our employees and investors.”

Siemens claims that deconsolidation potentially unlocks long-term value for shareholders as a more focused technology company. Separating the Siemens Healthineers unit delivers a highly synergistic portfolio, the company said in a news release.

The move makes Siemens’ stake in Siemens Healthineers a significant minority, allowing “greater capital allocation flexibility.” It still enables the company to participate in what it labeled “the attractive business of Siemens Healthineers” as a minority shareholder.

CFO Ralf P. Thomas says each company has “a strong financial profile” with strategic flexibility in their respective markets. The company hopes to enable both organizations to operate “with greater agility and focus,” he added.

Siemens believes this enables the Healthineers unit to benefit from a higher free float and greater attractiveness for the capital market as a leading pure-play medtech company. The company intends to provide future updates on the structure and timing of the transaction, which remains subject to final regulatory clearances and approvals. It expects to offer an update in the second quarter of 2026.

“Today marks the beginning of the next stage of growth for Siemens. By giving up the controlling majority in Siemens Healthineers, we are focusing on a highly synergistic Siemens portfolio” said Roland Busch, president and CEO of Siemens AG. “This is a logical next step in executing our strategy of combining the real and the digital worlds, focusing on accelerated profitable growth of our digital businesses, connected and software-defined hardware and industrial AI.”

The post Siemens to reduce Siemens Healthineers stake in spin-off appeared first on Medical Device News by Guided Solutions.

The US-based company will receive $440m at the deal’s closing, with additional payments up to $25m, subject to certain 2026 revenue targets being achieved. Around 100 Organon employees are expected to transfer to Laborie as part of the agreement. The transaction is expected to complete by Q1 2026.

Neither Organon nor Laborie immediately responded to Medical Device Network’s request for more details around what the revenue targets would be.

Originally developed by Alydia Health, the JADA system comprises an intrauterine vacuum designed to control and treat abnormal postpartum uterine bleeding or haemorrhage. The device gained US Food and Drug Administration (FDA) clearance in 2020 and was then acquired by Organon for $240m in 2021.

Reflecting on the sale of JADA, Organon’s interim CEO Joseph Morrissey said the deal would improve capacity on Organon’s balance sheet to “be able to pursue other growth opportunities in women’s health biopharma in the future.”

Organon span off from MSD in 2021, inheriting debt of around $9.5bn. According to Organon’s Q2 2025 financials, its debt remains at $8.9bn.

While JADA’s sales grew 40% in 2024 to $61m, it appears evident that alongside paying down the debt on its balance sheet, Organon is choosing to move away from medtech women’s health devices to renew its focus on its women’s health biopharma range. Nexplanon is the company’s top-selling biopharma product, achieving around $179m in revenue in Q2 2025.

The contraceptive implant recently took centre stage in a sales malpractice imbroglio uncovered by Organon’s board in October 2025 that resulted in the company’s CEO Kevin Ali standing down from his position. According to the board’s probe, Organon was conducting “improper” wholesaler sales practices, whereby it encouraged US-based wholesalers to buy more Nexplanon units than they required.

Organon’s stock value dropped 20.9% from $9.16 at market close on 24 October to $7.25 at market open on 27 October following the publication of the probe’s findings. The sales malpractice revelation further doused the company’s stock performance, which has decreased by more than 60% in the past year to a current price per share of $6.61, down from around $17-$18 in November 2024.

The post Organon divests JADA system to Laborie in $465m deal appeared first on Medical Device News by Guided Solutions.

The deal adds new robotic capabilities to Zimmer Biomet’s growing surgical robotics portfolio. The company said Monogram’s surgeon-guided, CT-based systems will complement its existing Rosa Robotics platform and other navigation and mixed-reality tools used in joint replacement and other orthopedic procedures. The deal was previously announced in July.

Related: Natus expands neurodiagnostic AI capabilities with Holberg buy

“By bringing Monogram into the Zimmer Biomet innovation ecosystem, we have set a bold course to become the first orthopedic company to offer a fully autonomous robotic solution complementing our current robotic and navigation offerings,” CEO Ivan Tornos said. “We aim to provide surgeons the broadest choice in robotics and navigation across a wide range of procedures and care settings. I want to personally welcome the Monogram team to Zimmer Biomet, as their talent and technology will accelerate our innovation pipeline, deepen our value to surgeons and strengthen our long-term growth strategy.”

Monogram’s semi-autonomous total knee arthroplasty system received FDA 510(k) clearance in March 2025, with commercialization planned alongside Zimmer Biomet implants by early 2027. The company began a clinical study in July 2025 for its fully autonomous version.

The acquisition also allows Zimmer Biomet to offer CT-based and imageless robotic options while developing one of the first fully autonomous surgical robotic systems. It further strengthens its competitive position against other orthopedic surgical robot developers like Stryker, Smith+Nephew and Johnson & Johnson.

Under the merger agreement, each outstanding share of Monogram common stock converted into $4.04 in cash plus non-tradeable contingent value rights worth up to $12.37 if development, regulatory and revenue milestones are met by 2030.

Monogram shares stopped trading on Nasdaq before the market opened Oct. 7 and will be delisted.

The post Zimmer Biomet completes acquisition of Monogram Technologies to expand orthopedic robotics portfolio appeared first on Medical Device News by Guided Solutions.

With the closing of the deal, Elutia says it can leverage its proven drug-eluting biologics platform with a more concentrated focus on advancing its NXT-41x offering. NXT-41x is a next-gen antibiotic biomatrix for breast reconstruction. It directly addresses the root causes of reconstruction infections following mastectomy. The biomatrix combines handling, biologics and an extended antibiotic release to provide protection while supporting tissue regeneration.

Related: Natus expands neurodiagnostic AI capabilities with Holberg buy

“With our significantly strengthened financial position, we plan to bring NXT-41x to market in the first half of 2027,” said Dr. Randy Mills, CEO of Elutia. “We are confident we have the people, technology, and resources to reshape the breast reconstruction treatment paradigm and accelerate our path to positive cash flow. I want to thank the entire Elutia CRU for their relentless work to enable patients everywhere to thrive without compromise.”

Meanwhile, Boston Scientific adds new offerings to its portfolio of implantable devices that includes leading defibrillators and pacemakers.

Elutia designed EluPro to prevent post-operative complications in patients with implantable cardiac devices. Those include pacemakers and internal defibrillators. The system received FDA clearance in June 2024 and also has approval for use with additional devices. That extends to neuromodulators and neurostimulators for pain management, epilepsy, incontinence and sleep apnea.

CanGaroo is a porcine small intestine submucosa extracellular matrix that creates a healthy pocket for implanted devices. The bioenvelope stabilizes the implantable devices, such as pacemakers and defibrillators, as well.

The post Elutia closes $88M bioenvelope sale to Boston Scientific appeared first on Medical Device News by Guided Solutions.

Middleton, Wisconsin–based Natus touts Holberg as the developer of the world’s first AI model capable of automatic and comprehensive clinical EEG interpretation with accuracy “on par with leading medical experts.” The acquisition brings the Holberg EEG technology into the neurodiagnostics portfolio at Natus. It creates new opportunities to advance brain health through smarter, more accessible solutions.

Related: RDS raises €14m to bolster market penetration of patient monitoring wearable

Holberg’s AI model delivers efficiency and diagnostic confidence in interpreting complex EEG data. The company’s flagship autoScore innovation came to the U.S. market in 2024. Using a deep-learning model trained on more than 30,000 EEG recordings, it alleviates the demands on clinical resources.

By integrating it with trusted EEG and neurodiagnostic solutions at Natus, providers can benefit from streamlined workflows, enhanced accuracy and improved patient outcomes. Natus plans to offer it exclusively on its NeuroWorks software for routine EEG, long-term monitoring and ambulatory EEG studies. It has FDA 510(k) clearance and CE mark.

Natus already offers a series of solutions to screen, diagnose, and treat disorders affecting the brain and neural pathways. That includes BrainWatch, its point-of-care EEG solution driven by AI, which it launched in May.

“Bringing Holberg EEG into the Natus family is an exciting and strategic milestone for our company and the field of neurodiagnostics,” said Chris Landon, CEO of Natus. “This acquisition allows us to accelerate the adoption of cutting-edge AI technology that empowers healthcare providers and technologists with faster, more accurate EEG interpretation – improving patient outcomes worldwide. We are proud to unite our deep heritage in neuro care with Holberg’s groundbreaking innovation, creating a powerful force for advancing brain health for decades.”

The post Natus expands neurodiagnostic AI capabilities with Holberg buy appeared first on Medical Device News by Guided Solutions.

Through the acquisition, the terms of which have not been publicly disclosed, Glooko will inherit Monarch’s EndoTool Glucose Management System. Used in hospitals to help manage blood glucose levels in critically ill patients, the platform received US Food and Drug Administration (FDA) approval in 2006.

Related: Edwards buys remaining stake of Vectorious Medical Technologies and its heart implant

Glooko’s diabetes platform is used by clinicians and healthcare facilities to link medical and connected devices used by diabetics into a singular platform. Adding EndoTool to the platform will further support the company’s efforts to deliver a full-spectrum ‘hospital-to-home’ diabetes solution to improve patient outcomes and streamline operational workflows, according to Glooko’s CEO Mike Alvarez.

Glooko’s chief medical and strategy officer Mark Clements commented: “By integrating EndoTool with Glooko’s outpatient platform, we believe we will be better able to ensure safer care transitions for people with diabetes, help hospitals meet quality and regulatory requirements, and deliver measurable improvements in patient outcomes across the continuum.”

Based in California, Glooko’s acquisition of Monarch marks a continuation of the company’s efforts to develop its platform and expand its global footprint. In November 2024, Glooko completed a $100m Series F financing round to expand into the Middle East and Asia.

At the start of this year, Glooko partnered with Danish digital therapeutics company Hedia to launch a combined diabetes care technology provision in the UK to enhance support for diabetic patients who require bolus insulin dosing support in their daily management.

Throughout 2025, Glooko has also continued adding to its existing roster of over 200 integrated devices, including an integration with Abbott’s FreeStyle Libre continuous glucose monitoring (CGM) device in a move that broadens the reach of Glooko’s platform to around 4.5 million patients who use Abbott’s device.

The global diabetes population is projected to hit 643 million by 2030, as per data from the International Diabetes Federation.

The post Glooko acquires Monarch to advance diabetes platform reach appeared first on Medical Device News by Guided Solutions.

The imaging giant stated that the purchase will enable it to integrate icometrix’s icobrain platform into existing MRI workflows, thereby meeting the growing demand for MRI in personalised treatment planning for conditions such as Alzheimer’s disease.

A standout provision of the Belgian company’s platform is icobrain aria, claimed to be the first US Food and Drug Administration (FDA)-cleared AI solution for detecting and quantifying amyloid-related imaging abnormalities (ARIA) – a side effect associated with amyloid-targeting pharmaceutical therapies used in Alzheimer’s disease treatment.

Related: Highridge Medical acquires spine surgery products from Accelus

Icometrix’s icobrain aria can identify ARIA-E (oedema/effusion) and ARIA-H (microhaemorrhages or haemosiderin deposits) from MR scans. Performing longitudinal analysis of ARIA occurrence over time, the tool is designed to give radiologists the ability to monitor Alzheimer’s disease patients’ response to anti-amyloid therapies.

GE HealthCare stated that it intends to expand patient access to the solution on all vendor MRI systems through commercial distribution and clinical integration.

GE HealthCare MR president and CEO Kelly Londy commented: “Along with our commitment to pushing the barriers of neuroscience research with our innovative MRI technology, we’re dedicated to strengthening our neurology portfolio and our MR imaging capabilities to provide advanced solutions to clinicians providing more precise care for patients both now and in the future.”

Eisai and Biogen’s Leqembi (lecanemab) and Eli Lilly’s Kisunla (donanemab), which received FDA approval in January 2023 and July 2024, respectively, represent the most significant disease-modifying treatments available for Alzheimer’s disease. The forecast is to generate global sales of approximately $3.6bn and $3.8bn, respectively, by 2033, as per GlobalData analysis.

However, the two drugs have struggled with reimbursement in several territories due to narrow benefit-to-risk ratios and the need for frequent brain imaging before and during treatment, the latter adding expense.

In Lilly’s clinical trials of Kisunla, ARIA-E and ARIA-H were among the most common serious side effects observed, with Alzheimer’s disease patients with the APOE ε4 homozygous genotype found to be at significantly higher risk for developing ARIA.

The post GE HealthCare bolsters MRI provision with icometrix acquisition appeared first on Medical Device News by Guided Solutions.